Market Size of Europe Novel Drug Delivery System (NDDS) Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 8.10 % |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Europe Novel Drug Delivery Systems Market Analysis
European novel drug delivery system market primarily driven by technological advancements promoting the development of NDDS and the rising need for controlled release of drugs.
Nowadays, for the treatment of chronic disorders as well as for controlling the release of active ingredients from drug products, a unique delivery system, the controlled release drug delivery system (CRDDS) of novel drug delivery, is included in the drug delivery technique. Majority of the active pharmaceutical ingredients are distributed in the form of CRDDS. A controlled drug delivery system is, thus, a very reliable, potential form of novel drug delivery technique, in which the drug is subjected to the appropriate pharmaceutical drug dosage form and its release is predetermined, making the release controlled at particular sites of action (cells, tissues, and organs).
Transdermal patches, implants, nasal systems, microcapsules, etc., are some of the common systems that are considered under controlled release systems. The need for controlled release of drugs is propelling the increasing demand for unique and innovative systems for drug delivery, where this novel drug delivery system plays a significant role in the advancement of controlled release of drugs, thereby driving the growth of the market, over the forecast period.
Europe Novel Drug Delivery Systems Industry Segmentation
As per the scope of this report, novel drug delivery system refers to the approaches, technologies, systems, and formulations for transporting a pharmaceutical compound in the body as required to safely achieve its desired therapeutic effects. It is a novel system for the delivery of drugs, different from the conventional drug delivery systems. The market is segmented by route of administration, mode of NDDS, and geography.
| By Route of Administration | |
| Oral Drug Delivery Systems | |
| Injectable Drug Delivery Systems | |
| Pulmonary Drug Delivery Systems | |
| Transdermal Drug Delivery Systems | |
| Other Routes of Administration |
| By Mode of NDDS | |
| Targeted Drug Delivery Systems | |
| Controlled Drug Delivery Systems | |
| Modulated Drug Delivery Systems |
| Geography | ||||||||
|
Europe Novel Drug Delivery System (NDDS) Market Size Summary
The European novel drug delivery systems market is experiencing significant growth, driven by technological advancements and the increasing demand for controlled drug release mechanisms. These systems, particularly the controlled release drug delivery systems (CRDDS), are integral in managing chronic disorders by ensuring that active pharmaceutical ingredients are released at predetermined sites, such as specific cells, tissues, or organs. Common forms of these systems include transdermal patches, implants, nasal systems, and microcapsules. The rising need for innovative drug delivery solutions is propelling the market forward, as these systems play a crucial role in enhancing the efficacy and precision of drug administration.
Targeted drug delivery systems are particularly noteworthy for their ability to deliver drugs directly to diseased tissues, offering controlled and prolonged therapeutic effects. This method is especially beneficial in treating chronic conditions like cardiovascular diseases, diabetes, and cancer, with the latter being a primary focus due to the anticipated increase in cancer cases. The market is characterized by the presence of major players such as Abbott Laboratories, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche AG, and Sanofi SA, who are heavily invested in research and development to create stable and safe formulations. The ongoing technological developments within the market underscore its dynamic nature and the continuous push towards more effective drug delivery solutions.
Europe Novel Drug Delivery System (NDDS) Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Technological Advancements Promoting the Development of NDDS
-
1.2.2 Rising Need for the Controlled Release of Drugs
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Guidelines
-
1.3.2 Stability Issues
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Route of Administration
-
2.1.1 Oral Drug Delivery Systems
-
2.1.2 Injectable Drug Delivery Systems
-
2.1.3 Pulmonary Drug Delivery Systems
-
2.1.4 Transdermal Drug Delivery Systems
-
2.1.5 Other Routes of Administration
-
-
2.2 By Mode of NDDS
-
2.2.1 Targeted Drug Delivery Systems
-
2.2.2 Controlled Drug Delivery Systems
-
2.2.3 Modulated Drug Delivery Systems
-
-
2.3 Geography
-
2.3.1 Europe
-
2.3.1.1 United Kingdom
-
2.3.1.2 Germany
-
2.3.1.3 France
-
2.3.1.4 Italy
-
2.3.1.5 Spain
-
2.3.1.6 Rest of Europe
-
-
-
Europe Novel Drug Delivery System (NDDS) Market Size FAQs
What is the current Europe Novel Drug Delivery System (NDDS) Market size?
The Europe Novel Drug Delivery System (NDDS) Market is projected to register a CAGR of 8.10% during the forecast period (2024-2029)
Who are the key players in Europe Novel Drug Delivery System (NDDS) Market?
GlaxoSmithKline PLC, Pfizer Inc., Sanofi SA, AstraZeneca and Novartis AG are the major companies operating in the Europe Novel Drug Delivery System (NDDS) Market.
